BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: He N, Ghassaban K, Huang P, Jokar M, Wang Y, Cheng Z, Jin Z, Li Y, Sethi SK, He Y, Chen Y, Gharabaghi S, Chen S, Yan F, Haacke EM. Imaging iron and neuromelanin simultaneously using a single 3D gradient echo magnetization transfer sequence: Combining neuromelanin, iron and the nigrosome-1 sign as complementary imaging biomarkers in early stage Parkinson's disease. Neuroimage 2021;230:117810. [PMID: 33524572 DOI: 10.1016/j.neuroimage.2021.117810] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Langley J, Hwang KS, Hu XP, Huddleston DE. Nigral volumetric and microstructural measures in individuals with scans without evidence of dopaminergic deficit. Front Neurosci 2022;16. [DOI: 10.3389/fnins.2022.1048945] [Reference Citation Analysis]
2 He N, Chen Y, Lewitt PA, Yan F, Haacke EM. Response to “Neuromelanin? MRI of Noradrenergic and Dopaminergic Neurons”. Magnetic Resonance Imaging 2022. [DOI: 10.1002/jmri.28481] [Reference Citation Analysis]
3 Zhang D, Yao J, Sun J, Tong Q, Zhu S, Wang J, Chen L, Ma J, He H, Wu T. Quantitative Susceptibility Mapping and Free Water Imaging of Substantia Nigra in Parkinson’s Disease. JPD 2022. [DOI: 10.3233/jpd-223499] [Reference Citation Analysis]
4 Wen J, Guo T, Wu J, Bai X, Zhou C, Wu H, Liu X, Chen J, Cao Z, Gu L, Pu J, Zhang B, Zhang M, Guan X, Xu X. Nigral Iron Deposition Influences Disease Severity by Modulating the Effect of Parkinson’s Disease on Brain Networks. JPD 2022. [DOI: 10.3233/jpd-223372] [Reference Citation Analysis]
5 Ben Bashat D, Thaler A, Lerman Shacham H, Even-Sapir E, Hutchison M, Evans KC, Orr-Urterger A, Cedarbaum JM, Droby A, Giladi N, Mirelman A, Artzi M. Neuromelanin and T(2)*-MRI for the assessment of genetically at-risk, prodromal, and symptomatic Parkinson's disease. NPJ Parkinsons Dis 2022;8:139. [PMID: 36271084 DOI: 10.1038/s41531-022-00405-9] [Reference Citation Analysis]
6 Suo X, Li Z, Zuo C, Lan H, Pan N, Lui S, Gong Q. Research progress of psychoradiology in geriatric neurodegenerative diseases. Sci Sin -Vitae 2022. [DOI: 10.1360/ssv-2022-0168] [Reference Citation Analysis]
7 Li C, Zhou J, Wang D, Li X, Jiang S, Zhang Y, Wen Z, Wang G, Yan F, Chen M. Amide proton transfer imaging of Alzheimer's disease and Parkinson's disease. Magnetic Resonance Letters 2022. [DOI: 10.1016/j.mrl.2022.10.002] [Reference Citation Analysis]
8 He N, Chen Y, LeWitt PA, Yan F, Haacke EM. Application of Neuromelanin MR Imaging in Parkinson Disease. J Magn Reson Imaging 2022. [PMID: 36017746 DOI: 10.1002/jmri.28414] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Foley PB, Hare DJ, Double KL. A brief history of brain iron accumulation in Parkinson disease and related disorders. J Neural Transm (Vienna) 2022. [PMID: 35534717 DOI: 10.1007/s00702-022-02505-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 He N, Wu B, Liu Y, Zhang C, Cheng J, Gao B, Miao Y, Wu W, Wang L, Sun R, Sun W, Xu H, Bai Y, Wang M, Chai C, Xia S, Zheng Q, Li Y, Qin Y, Liao W, Chen Y, Jokar M, Wang Y, Yan F, Haacke EM. STAGE as a multicenter, multivendor protocol for imaging Parkinson’s disease: a validation study on healthy controls. Chin J Acad Radiol 2022;5:47-60. [DOI: 10.1007/s42058-022-00089-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Lee JY, Martin-Bastida A, Murueta-Goyena A, Gabilondo I, Cuenca N, Piccini P, Jeon B. Multimodal brain and retinal imaging of dopaminergic degeneration in Parkinson disease. Nat Rev Neurol 2022. [PMID: 35177849 DOI: 10.1038/s41582-022-00618-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
12 Jin Z, Wang Y, Jokar M, Li Y, Cheng Z, Liu Y, Tang R, Shi X, Zhang Y, Min J, Liu F, He N, Yan F, Haacke EM. Automatic detection of neuromelanin and iron in the midbrain nuclei using a magnetic resonance imaging ‐based brain template. Human Brain Mapping. [DOI: 10.1002/hbm.25770] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
13 Xiao B, He N, Wang Q, Shi F, Cheng Z, Haacke EM, Yan F, Shen D. Stability of AI-Enabled Diagnosis of Parkinson's Disease: A Study Targeting Substantia Nigra in Quantitative Susceptibility Mapping Imaging. Front Neurosci 2021;15:760975. [PMID: 34887722 DOI: 10.3389/fnins.2021.760975] [Reference Citation Analysis]
14 Langley J, Huddleston DE, Hu X. Nigral diffusivity, but not free water, correlates with iron content in Parkinson's disease. Brain Commun 2021;3:fcab251. [PMID: 34805996 DOI: 10.1093/braincomms/fcab251] [Reference Citation Analysis]
15 Wieland L, Fromm S, Hetzer S, Schlagenhauf F, Kaminski J. Neuromelanin-Sensitive Magnetic Resonance Imaging in Schizophrenia: A Meta-Analysis of Case-Control Studies. Front Psychiatry 2021;12:770282. [PMID: 34777070 DOI: 10.3389/fpsyt.2021.770282] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
16 Liu Y, Xiao B, Zhang C, Li J, Lai Y, Shi F, Shen D, Wang L, Sun B, Li Y, Jin Z, Wei H, Haacke EM, Zhou H, Wang Q, Li D, He N, Yan F. Predicting Motor Outcome of Subthalamic Nucleus Deep Brain Stimulation for Parkinson's Disease Using Quantitative Susceptibility Mapping and Radiomics: A Pilot Study. Front Neurosci 2021;15:731109. [PMID: 34557069 DOI: 10.3389/fnins.2021.731109] [Cited by in F6Publishing: 1] [Reference Citation Analysis]